Quick Answer
Emmaus Life Sciences, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $12.45 million for the year ending 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -25.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Emmaus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Emmaus Life Sciences, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 24.3%.
- Historical annual values: Fiscal year 2025: $12.45 million | Fiscal year 2024: $16.65 million | Fiscal year 2023: $29.60 million | Fiscal year 2022: $18.39 million | Fiscal year 2021: $20.61 million | Fiscal year 2020: $23.17 million | Fiscal year 2019: $22.75 million | Fiscal year 2018: $16.46 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: